Bibliografia UJ CM

1/2
Ajay K. Gopal, Brad S. Kahl, Sven Vos, de, Nina D. Wagner-Johnston, Stephen J. Schuster, Wojciech J. Jurczak, Ian W. Flinn, Christopher R. Flowers, Peter Martin, Andreas Viardot, Kristie A. Blum, Andre H. Goy, Andrew J. Davies, Pier Luigi Zinzani, Martin Dreyling, Dave Johnson, Langdon L. Miller, Leanne Holes, Daniel Li, Roger D. Dansey, Wayne R. Godfrey, Gilles A. Salles.
PI3KΔ inhibition by idelalisib in patients with relapsed indolent lymphoma.
New England Journal of Medicine
2014 : Vol. 370, nr 11, s. 1008-1018, il., bibliogr., abstr.
p-ISSN: 0028-4793
AZ
ORG
AIF
IF: 55.873
Adres url:
2/2
Bertrand Coiffier, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven Vos, de, Michael Crump, Ofer Shpilberg, Dixie-Lee Esseltine, Eugene Zhu, Christopher Enny, Panteli Theocharous, Helgi Velde, van de, Yusri A. Elsayed, Pier Luigi Zinzani, LYM-3001 study investigators.
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma : a randomised phase 3 trial.
Lancet. Oncology
2011 : Vol. 12, nr 8, s. 773-784, il., bibliogr. 44 poz., sum.
p-ISSN: 1470-2045
AZ
ORG
AIF
IF: 22.589
Wyświetl ponownie stosując format: